

## Index to Volume 2

### Author Index

- Abraham, E. P., 140  
 Alling, D. W., 599  
 Angel, R., 633  
 Arana, A., 633  
 Arechavala, A., 643  
 Barnishan, J., 841  
 Beale, A. J., 960  
 Bennett, J. E., 535  
 Borgers, M., 520, 570  
 Borelli, D., 592  
 Böttiger, M., 274  
 Brandt, C. D., 459  
 Brass, C., 656  
 Burakoff, S. J., 62  
 Campbell, S. C., 656  
 Casala, A. M., 596  
 Chanock, R. M., 421, 459  
 Chatigny, M. A., 713  
 Choppin, P. W., 40  
 Citron, D. M., 914  
 Clayton, Y. M., 600  
 Cobb, J. M., 546  
 Cobbs, C. G., 889  
 Crumpacker, C. S., II, 78  
 Cucé, L. C., 650  
 Densen, P., 817  
 Diaz, M., 651  
 Dismukes, W. E., 535  
 Donovan, W., 666  
 Dom, J., 674  
 Dony, J., 674  
 Drouhet, E., 606  
 Drutz, D. J., 535, 551, 661  
 Dupont, B., 606  
 Eckert, E. A., 952  
 Edelman, R., 370  
 Elsbach, P., 106  
 Enders, J. F., 493  
 Fagraeus, A., 274  
 Fass, R. J., 841  
 Finberg, R., 62  
 Finegold, S. M., 914  
 Finestine, N., 674  
 Fleming, A., 129  
 Fishaut, M., 352  
 Fox, J. P., 277  
 Fregoso-Dueñas, F., 620  
 Fuentes, J., 633  
 Galgiani, J. N., 656  
 Galimberti, R., 596, 643  
 Gallagher, M. R., 352  
 Gardner, I. D., 801  
 Geiseler, J. P., 725  
 George, W. L., 914  
 Gerding, D. N., 340  
 Gerin, J. L., 470  
 Gershon, A. A., 393  
 Ghosh, H. P., 26  
 Glezen, W. P., 408  
 Gómez, I., 633  
 González, J., 651  
 González, J. G., 651  
 Graybill, J. R., 535, 551, 661  
 Greenberg, H. B., 459  
 Grossman, P. L., 761  
 Guze, L. B., 169  
 Hall, C. B., 384  
 Hanifin, J. M., 578  
 Hammond, G. W., 867  
 Hart, G., 701  
 Harvey, R. P., 559  
 Hay, R. J., 600  
 Hirschmann, J. V., 1  
 Hook, E. W., III, 746  
 Huang, A. S., 24  
 Iglesia de Elias Costa, M. R., 596  
 Inui, T. S., 1  
 Isenberg, R. A., 559  
 Kalica, A. R., 459  
 Kapikian, A. Z., 459  
 Katz, S. L., 351  
 Kim, H. W., 459  
 Kirby, B. D., 914  
 Kirkpatrick, C. H., 599  
 Klein, J. O., 351  
 Lang, D. J., 449  
 Legendre, R., 586, 674  
 Leiderman, E., 633  
 Levin, S., 725  
 Levine, H. B., 546, 661  
 Lipsky, B. A., 746  
 Lorber, B., 207  
 Lundberg, D., 661  
 Madero, D., 651  
 Maitra, S. K., 169  
 Mandell, G. L., 817  
 McAuliffe, V. J., 470  
 Mejia, G., 633  
 Mescher, M. F., 62  
 Mills, E. L., 505  
 Moens, M., 674  
 Montgomerie, J. Z., 196  
 Moses, V. K., 725  
 Murphy, B. R., 421  
 Musher, D. M., 864  
 Negroni, R., 596, 643  
 Nelson, K. E., 725  
 Nieman, R. E., 207  
 North, E., 811, 962 (erratum)  
 Notter, D. T., 761  
 Ogra, P. L., 352  
 Parker, F., 578  
 Parrott, R. H., 459  
 Pavri, K. M., 142  
 Pesanti, E., 153  
 Petersen, E. A., 599  
 Peterson, L. R., 340  
 Plorde, J. J., 746  
 Plotkin, S. A., 433, 839 (erratum)  
 Prasad, S. R., 142  
 Prusiner, S. B., 713  
 Purcell, R. H., 470  
 Quie, P. G., 505  
 Reiss, C. S., 62  
 Reddi, K. T., 725  
 Remington, J. S., 535, 761  
 Restrepo, A., 519, 633  
 Robbins, F. C., 493  
 Roberts, F. J., 329  
 Robertson, M. H., 578  
 Robledo, M., 633  
 Robles, A. M., 643  
 Rodriguez, M., 582  
 Rodriguez, M. D., 661  
 Rodriguez, W. J., 459  
 Rosenberg, S. A., 761  
 Ronald, A. R., 867  
 Salk, D., 228, 243, 258  
 Sampaio, S. A. P., 650  
 Sanders, C. C., 182  
 Sanders, W. E., Jr., 182  
 Sapico, F. L., 196  
 Scatliff, J., 867  
 Schaad, U. B., 880  
 Scheid, A., 40  
 Scheijgrond, H., 674  
 Schot, M. C., 169  
 Schuermans, V., 674  
 Sherman, E., 867  
 Slutchuk, M., 867  
 Smith, A. A., 746  
 Stamm, A. M., 889  
 Steltz, M., 586  
 Stevens, D. A., 519, 535, 559, 633, 656  
 Sugarman, B., 153  
 Sutter, V. L., 914  
 Symoens, J., 674  
 Thienpont, D., 570  
 Tuculet, M. A., 643  
 Utz, J. P., 519, 625  
 Van Cutsem, E., 551, 570  
 Vanegas, A. C., 633  
 van Furth, R., 104  
 Vestergaard, B. F., 899  
 Walker, R. I., 282  
 Weller, T. H., 493  
 Wells, R. S., 600  
 Welsh, O., 582, 651  
 Wickman, L., 319  
 Wilkinson, P. C., 293  
 Wilt, J. C., 867  
 Willemze, R., 282  
 Williams, D. M., 551  
 Wingfield, H. J., 600  
 Wroclawski, E. L., 650  
 Wyatt, R. G., 459  
 Yoshikawa, T. T., 169

## Subject Index

- Adjuvants, for viral vaccines, 370
- Aging, effect on susceptibility to infection, 801
- Alkaline phosphatase deficiency, of leukocytes, and neutrophil dysfunction, 512
- Amikacin, and other aminoglycosides, comparison of activity with that of sisomicin, 182
- Amphotericin B
  - and ketoconazole, combination therapy of experimental histoplasmosis and cryptococcosis, 551
  - antifungal action, 626
- Antibiotics
  - protein binding, pharmacokinetics and extravascular penetration, 340
  - sensitivity of isolates from blood cultures, 329
- Antifungal drugs
  - criteria for evaluation of therapeutic response, 535
  - mechanism of action, 520
  - therapy of systemic mycoses, 625
- Antimicrobial agents
  - in vitro susceptibilities of nonfermentative gram-negative bacilli other than *P. aeruginosa*, 841
  - in vivo development of resistance by microorganisms, and treatment failure, 153
  - prophylactic use, critique of recent trials, 1
  - quantitation by high pressure liquid chromatography, 169
- Arthritis, in meningococcal disease, 880
- Bacteria, and viruses, effects of leukocyte locomotion and chemotaxis, 293
- Biohazards of investigations on the transmissible spongiform encephalopathies, 713
- Blastomycosis
  - in a mouse model, therapy with ketoconazole and other imidazoles, 559
  - ketoconazole therapy, 606
- Candidosis
  - and other mycoses, ketoconazole therapy, 650
  - chronic mucocutaneous, ketoconazole therapy, 599, 600, 606
  - experimental, ketoconazole therapy, 570
  - vulvovaginal, ketoconazole therapy, 620
- Chediak-Higashi syndrome, neutrophil dysfunction, 510
- Chemotaxis, and locomotion of leukocytes, effects of bacteria and viruses, 293
- Chromatography, high pressure, liquid, for quantitation of antimicrobial agents, 169
- Chromomycosis, and other mycoses, ketoconazole therapy, 650
- Chronic granulomatous disease, neutrophil dysfunction, 505
- Citrobacter infections in humans, review of clinical experience and literature, 746
- Coccidioidomycosis
  - ketoconazole therapy, 651
  - murine, early and late ketoconazole therapy, 546
- Control, of infectious diseases by screening, evaluation of control program for gonorrhea and syphilis, 701
- Creutzfeldt-Jakob disease, biohazards of investigation, 713
- Cryptococcosis and histoplasmosis, combined therapy with amphotericin B and ketoconazole, 551
- Cultures, of blood, positive, identification and source of microorganisms and antibiotic sensitivity, 329
- Cytomegalovirus, immunoprophylaxis, review of current status, prospects, and problems, 449
- Dengue, hemorrhagic fever and shock syndrome, role of T suppressor cells, 142
- Dermatomycoses, ketoconazole therapy, 582
- Dermatophytoses
  - comparison of ketoconazole and griseofulvin therapy, 586
  - unresponsive to griseofulvin, ketoconazole therapy, 578
- Down's syndrome, and leukocyte dysfunction, 512
- Drug abuse, iv, and vertebral osteomyelitis, case reports and review, 196
- Epidemiology
  - of community-acquired purulent meningitis, review of 1,316 cases during 1954-1976, 725
  - of Heine-Medin's disease (poliomyelitis) (classic description), 319
  - of plague in Early Modern Europe, Swiss epidemic of 1628-1630, 952
- Fleming, Alexander, discovery of penicillin, history, 140
- Flucytosine, antifungal action, 520, 526
- Gastroenteritis, due to rotaviruses, immunization of infants and young children, 459
- Gentamicin, and other aminoglycosides, comparison of activity with that of sisomicin, 182
- Glucose-6-phosphate dehydrogenase deficiency, neutrophil dysfunction, 512
- Glutathione system, defective, and neutrophil metabolism, 512
- Glycoproteins, of animal viruses, 24-103
  - cell-mediated immunity to, 62
  - role in adsorption, penetration, and pathogenicity, 40
  - role in infectious disease processes, 78
  - synthesis and maturation, 26
- Gonorrhea, and syphilis, control by screening, evaluation of control program, 701
- Granuloma, lingual, due to *C. albicans*, ketoconazole therapy, 606
- Granulopoiesis, regulation, and neutrophil kinetics, 282
- Griseofulvin
  - antifungal action, 520
  - compared with ketoconazole for therapy of dermatophytoses, 586
- Hamycin, antifungal action, 625
- Hepatitis, type B, review of current prospects for a safe and effective vaccine, 470
- Herpes simplex virus antigens and antibodies, studies based on quantitative immunoelectrophoresis, 899
- Histoplasmosis, ketoconazole therapy, 606, 643
- Histoplasmosis and cryptococcosis, experimental, combined therapy with amphotericin B and ketoconazole, 551
- Hodgkin's, disease and infection, study of 300 consecutive adult patients, 761
- Hydroxystilbamidine isethionate, antifungal action, 626
- Imidazole derivatives, antifungal action, 520, 625
- Imidazole derivatives (including ketoconazole)
  - activity and synergy in vitro; pharmacology and therapy of experimental blastomycosis, 559

- mechanism of antifungal activity, 520
- Immunity, cell-mediated, to viral glycoproteins, 62
- Immunoelectrophoresis, quantitative, of herpes simplex virus antigens and antibodies, 899
- Infection
  - and Hodgkin's disease, a study of 300 consecutive adult patients, 761
  - susceptibility to, effect of aging, 801
- Infectious diseases, control by screening, use of gonorrhea and syphilis as models, 701
- Influenza
  - immunoprophylaxis with temperature-sensitive and cold-adapted mutant viruses, 421
  - in children, risk and prophylaxis, 408
- Iodides, antifungal action, 625
- Ketoconazole
  - activity and synergy in vitro; pharmacology and therapy of experimental blastomycosis, 559
  - and amphotericin B, combination therapy of experimental histoplasmosis and cryptococcosis, 551
  - compared with griseofulvin for therapy of dermatophytoses, 586
  - First International Symposium
    - articles in English, 519-650
    - abstracts in Spanish, 692-699
  - in experimental candidosis, 570
  - therapy
    - for chromomycosis, 650
    - for chronic mucocutaneous candidosis, 599, 600, 606
    - for coccidioidomycosis, 651
    - for dermatomycoses, 592
    - for dermatophyte infections unresponsive to griseofulvin, 578
    - for histoplasmosis, 643
    - for lobomycosis, 650
    - for murine coccidioidomycosis, 546
    - for mycetoma, 650
    - for onychomycosis, 596
    - for paracoccidioidomycosis, 633, 643, 650
    - for pityriasis versicolor, 592
    - for superficial and systemic mycoses, 606
- Kuru, biohazards of investigation, 713
- Leukocytes, locomotion and chemotaxis, effects of bacteria and viruses, 293
- Listeriosis, in adults, changing pattern, case reports and review, 207
- Lobomycosis, and other mycoses, ketoconazole therapy, 650
- Mannosidosis, and neutrophil dysfunction, 512
- Man-Hegglin anomaly, and neutrophil dysfunction, 513
- Meningitis, purulent, community-acquired, review of 1,316 cases during 1954-1976, 725
- Microorganisms, strategy vs. phagocytes, 817
- Mycetoma, and other mycoses, ketoconazole therapy, 650
- Mycoses, systematic, chemotherapy, 625
- Neisseria meningitidis*, disease due to, and arthritis, 880
- Neutrophil kinetics, and regulation of granulopoiesis, 282
- Onychomycosis, ketoconazole therapy, 596
- Osteomyelitis, vertebral, in iv drug abusers, case reports and review, 196
- Pelger-Huet anomaly, and neutrophil dysfunction, 513
- Penicillin discovery by A. Fleming, 129 (classic paper), 140
- Penicillium*, antibacterial action of cultures, and use in isolation of *B. influenzae*, 129 (classic paper)
- Phagocytes, strategy vs. microbial tactics, 817
- Phagocytic cells
  - factors in degradation of microorganisms, 106
  - in defense against infection (introduction to series), 104
- Pharmacokinetics and extravascular penetration of antibiotics, influence of protein binding, 340
- Pityriasis versicolor, therapy with ketoconazole, 592
- Plague, seasonality in Early Modern Europe, Swiss epidemic of 1628-1630, 952
- Pneumonia, due to group C *Streptococcus*, case report and literature review, 889
- Poliomyelitis
  - eradication in the U.S., use of live and killed vaccines, 228, 243, 258, 277
  - vaccination in Sweden, use of killed vaccine, 274
- Poliomyelitis (Heine-Medin's disease), epidemiology, 319 (classic paper)
- Poliomyelitis viruses, cultivation in tissue culture, 493 (classic paper)
- Poliovirus vaccines, killed and live, 960
- Polyene antibiotics, antifungal action, 520
- Polymorphonuclear neutrophils, congenital disorders of function, 505
- Prophylaxis, use of antimicrobial agents, critique of recent trials, 1
- Protein binding of antibiotics, influence on pharmacokinetics and extravascular penetration, 340
- Rabies, vaccines, prepared in human cell culture, descriptions and usage, 433
- Resistance, of microorganisms to drugs, development in vivo, and treatment failure, 153
- Respiratory syncytial virus, immunoprophylaxis, 384
- Respiratory syncytial virus infection, immunoprophylaxis with temperature-sensitive and cold-adapted mutant viruses, 421
- Respiratory tract infections, temperature-sensitive and cold-adapted mutant viruses for immunoprophylaxis, 421
- Rotaviruses, vaccines for immunization of infants and young children against gastroenteritis, 459
- Saramycetin, antifungal action, 631
- Scrapie, biohazards of investigation, 713
- Screening, to control infectious diseases, evaluation of control program for gonorrhea and syphilis, 701
- Sepsis, due to gram-negative enteric bacilli, skin and soft-tissue manifestations, 854
- Sisomicin, comparison of activity with that of other aminoglycosides, 182
- Skin and soft-tissue manifestations of sepsis due to gram-negative enteric bacilli, 854
- Soft-tissue and cutaneous manifestations of sepsis due to gram-negative enteric bacilli, 854
- Streptococcus*, group C, cause of pneumonia, case report and literature review, 889
- Sulfonamides, antifungal action, 625
- Susceptibilities to 32 antimicrobial agents, in vitro, of nonfermentative gram-negative bacilli other than *P. aeruginosa*, 841
- Syphilis, and gonorrhea, control by screening, evaluation of

- control programs, 701
- T suppressor cells, role in dengue hemorrhagic fever and shock syndrome, 142
- Tinea capitis due to *T. schoenleinii* and *T. violaceum*, ketoconazole therapy, 606
- Tobramycin, and other aminoglycosides, comparison of activity with that of sisomicin, 182
- Tolnaftate, antifungal action, 520
- Transfer factor, leukocytic, antifungal action, 625
- Transmissible mink encephalopathy, biohazards of investigation, 713
- Vaccine
  - cytomegalovirus, review of current status, prospects, and problems, 449
  - influenza, indications for use in children, 408
  - rabies, prepared in human cell cultures, 433
  - respiratory syncytial virus, 384
  - rotaviruses, immunization of infants and young children against gastroenteritis, 459
  - type B hepatitis, review of current prospects, 470
  - varicella-zoster, live attenuated, 393
- Vaccines, viral
  - introduction to symposium, 351
  - use of adjuvants, 370
  - use of temperature-sensitive and cold-adapted mutants, 421
  - via the mucosal routes, 352
- Varicella-zoster vaccine, live attenuated, 393
- Viruses
  - and bacteria, effects on leukocyte locomotion and chemotaxis, 293
  - animal, glycoproteins, 24-103
    - introduction to series, 24
  - enveloped, animal, synthesis and maturation of glycoproteins, 26
  - role of glycoproteins in adsorption, penetration, and pathogenicity, 40

## Reviews of Infectious Diseases

*An Official Publication of the Infectious Diseases Society of America*

Edward H. Kass, *Editor*

John R. David, *Associate Editor*

Alice S. Huang, *Associate Editor*

Dennis L. Kasper, *Associate Editor*

Jerome O. Klein, *Associate Editor*

Mary M. Eichhorn Adams, *Assistant Editor*

Nancy Kurz Voynow, *Managing Editor*

Laura J. Liebler, *Editorial Assistant*

Julie McCoy, *Editorial Assistant*

### EDITORIAL BOARD

Robert Austrian, Philadelphia, Pa.

Michael M. Frank, Bethesda, Md.

D. Carleton Gajdusek, Bethesda, Md.

Sherwood L. Gorbach, Boston, Mass.

King K. Holmes, Seattle, Wash.

Harold Jennings, Ottawa, Canada

Richard T. Johnson, Baltimore, Md.

Samuel L. Katz, Durham, N.C.

Thomas C. Merigan, Jr., Stanford, Calif.

Kenneth Warren, New York, N.Y.

Frank E. Young, Rochester, N.Y.

### INTERNATIONAL BOARD OF EDITORS

Jacques F. Acar, Paris, France

Lawrence R. Freedman, Lausanne, Switzerland

Ralph van Furth, Leiden, The Netherlands

C. H. Huang, Beijing, China

Lars O. Kallings, Stockholm, Sweden

Jean Klastersky, Brussels, Belgium

P. Helena Mäkelä, Helsinki, Finland

Francis O'Grady, Nottingham, England

Theodore Sacks, Jerusalem, Israel

David A. J. Tyrrell, London, England

Yuichi Yamamura, Osaka, Japan

Volume 2  
January-December 1980

All rights reserved  
THE UNIVERSITY OF CHICAGO PRESS, CHICAGO  
THE UNIVERSITY OF CHICAGO PRESS LTD., LONDON S.W.1

---

© 1980 BY THE UNIVERSITY OF CHICAGO  
PUBLISHED BIMONTHLY JANUARY-DECEMBER

---

Printed in U.S.A.

## Reviews of Infectious Diseases

Volume 2

January-February 1980

Number 1

### Contents

#### Review Articles

Antimicrobial Prophylaxis: A Critique of Recent Trials. J. V. HIRSCHMANN and T. S. INUI . . . .	1
Viral Glycoproteins: A Collection of Reviews	
Introduction. ALICE S. HUANG . . . . .	24
Synthesis and Maturation of Glycoproteins of Enveloped Animal Viruses. HARA P. GHOSH	26
The Role of Viral Glycoproteins in Adsorption, Penetration, and Pathogenicity of Viruses. PURNELL W. CHOPPIN and ANDREAS SCHEID . . . . .	40
Cell-Mediated Immunity to Viral Glycoproteins. STEVEN J. BURAKOFF, CAROL S. REISS, ROBERT FINBERG, and MATTHEW F. MESCHER . . . . .	62
Viral Glycoproteins in Infectious Disease Processes. CLYDE S. CRUMPACKER II . . . . .	78

#### Serial Feature. Phagocytic Cells in the Defense Against Infection

Introduction. RALPH VAN FURTH . . . . .	104
Degradation of Microorganisms by Phagocytic Cells. PETER ELSBACH . . . . .	106

#### Classics in Infectious Diseases

On the Bacterial Action of Cultures of a Penicillium, with Special Reference to Their Use in the Isolation of <i>B. influenzae</i> . ALEXANDER FLEMING . . . . .	129
Fleming's Discovery. EDWARD P. ABRAHAM . . . . .	140

#### Hypothesis

T Suppressor Cells: Role in Dengue Hemorrhagic Fever and Dengue Shock Syndrome. KHORSHED M. PAVRI and S.R. PRASAD . . . . .	142
---	-----

Statement of Editorial Policy and Instructions to Authors . . . . .	147
---	-----

Volume 2

March-April 1980

Number 2

### Contents

#### Review Articles

Treatment Failures Secondary to in Vivo Development of Drug Resistance by Microorganisms. BARRETT SUGARMAN and EDWARD PESANTI . . . . .	153
---	-----



High-Pressure Liquid Chromatography for Quantitation of Antimicrobial Agents. THOMAS T. YOSHIKAWA, SHYAMAL K. MAITRA, MICHAEL C. SCHOTZ, and LUCIEN B. GUZE .....	169
Sisomicin: A Review of Eight Years' Experience. W. EUGENE SANDERS, JR., and CHRISTINE C. SANDERS .....	182
Vertebral Osteomyelitis in Intravenous Drug Abusers: Report of Three Cases and Review of the Literature. FRANCISCO L. SAPICO and JOHN Z. MONTGOMERIE .....	196
Listeriosis in Adults: A Changing Pattern. Report of Eight Cases and Review of the Literature, 1968-1978. ROGER E. NIEMAN and BENNETT LORBER .....	207
Eradication of Poliomyelitis in the United States. DARRELL SALK	
I. Live Virus Vaccine-Associated and Wild Poliovirus Disease .....	228
II. Experience with Killed Poliovirus Vaccine .....	243
III. Practical Considerations .....	258

#### Editorials

Polio Vaccination in Sweden. ASTRID FAGRAEUS and MARGARET BÖTTIGER .....	274
Eradication of Poliomyelitis in the United States: A Commentary on the Salk Reviews. JOHN P. FOX .....	277

#### Serial Feature

Neutrophil Kinetics and the Regulation of Granulopoiesis. RICHARD I. WALKER and ROEL WILLEMZE .....	282
Leukocyte Locomotion and Chemotaxis: Effects of Bacteria and Viruses. PETER C. WILKINSON .....	293

#### Classics in Infectious Diseases

On the Epidemiology of Heine-Medin's Disease. IVAR WICKMAN .....	319
--	-----

Volume 2

• May-June 1980 •

Number 3

#### Contents

##### Review Articles

A Review of Positive Blood Cultures: Identification and Source of Microorganisms and Patterns of Sensitivity to Antibiotics. F. J. ROBERTS .....	329
Influence of Protein Binding of Antibiotics on Serum Pharmacokinetics and Extravascular Penetration: Clinically Useful Concepts. LANCE R. PETERSON and DALE N. GERDING .....	340

##### Prospects for New Viral Vaccines: A Symposium

Introduction. JEROME O. KLEIN and SAMUEL L. KATZ .....	351
Viral Vaccination via the Mucosal Routes. PEARAY L. OGRA, MARK FISHAUT, and MARIE R. GALLAGHER .....	352
Vaccine Adjuvants. ROBERT EDELMAN .....	370



Prevention of Infections with Respiratory Syncytial Virus: The Hopes and Hurdles Ahead. CAROLINE BREESE HALL .....	384
Live Attenuated Varicella-Zoster Vaccine. ANNE A. GERSHON .....	393
Consideration of the Risk of Influenza in Children and Indications for Prophylaxis. W. PAUL GLEZEN .....	408
Use of Temperature-Sensitive and Cold-Adapted Mutant Viruses in Immunoprophylaxis of Acute Respiratory Tract Diseases. ROBERT M. CHANOCK and BRIAN R. MURPHY .....	421
Rabies Vaccine Prepared in Human Cell Cultures: Progress and Perspectives. STANLEY A. PLOTKIN .....	433
Cytomegalovirus Immunization: Status, Prospects, and Problems. DAVID J. LANG .....	449
Approaches to Immunization of Infants and Young Children Against Gastroenteritis Due to Rotaviruses. ALBERT Z. KAPIKIAN, RICHARD G. WYATT, HARRY B. GREENBERG, ANTHONY R. KALICA, HYUN WHA KIM, CARL D. BRANDT, WILLIAM J. RODRIGUEZ, ROBERT H. PARROTT, and ROBERT M. CHANOCK .....	459
Type B Hepatitis: A Review of Current Prospects for a Safe and Effective Vaccine. VINCENT J. MCAULIFFE, ROBERT H. PURCELL, and JOHN L. GERIN .....	470
Classics in Infectious Diseases	
The Cultivation of the Poliomyelitis Viruses in Tissue Culture. Nobel Lecture, 1954. JOHN F. ENDERS, FREDERICK C. ROBBINS, and THOMAS H. WELLER .....	493
Serial Feature. Phagocytic Cells in the Defense Against Infection	
Congenital Disorders of the Functions of Polymorphonuclear Neutrophils. ELAINE L. MILLS and PAUL G. QUIE .....	505

Volume 2

July-August 1980

Number 4

## Contents

Participants .....	vi
Introduction. ANGELA RESTREPO, DAVID A. STEVENS, and JOHN P. UTZ .....	519
Session I: Antifungal Drugs	
Mechanism of Action of Antifungal Drugs, with Special Reference to the Imidazole Derivatives. M. BORGERs .....	520
Discussion .....	534
Criteria for Evaluation of Therapeutic Response to Antifungal Drugs. WILLIAM E. DISMUKES, JOHN E. BENNETT, DAVID J. DRUTZ, JOHN R. GRAYBILL, JACK S. REMINGTON, and DAVID A. STEVENS .....	535
Discussion .....	544
Session II: Experimental Therapy	
Ketoconazole in Early and Late Murine Coccidioidomycosis. HILLEL B. LEVINE and JAMES M. COBB .....	546

Combination Therapy of Experimental Histoplasmosis and Cryptococcosis with Amphotericin B and Ketoconazole. JOHN R. GRAYBILL, DWIGHT M. WILLIAMS, ERIC VAN CUTSEM, and DAVID J. DRUTZ .....	551
Molecular Modifications of Imidazole Compounds: Studies of Activity and Synergy in Vitro and of Pharmacology and Therapy of Blastomycosis in a Mouse Model. ROBERT P. HARVEY, RICHARD A. ISENBERG, and DAVID A. STEVENS .....	559
Ketoconazole in Experimental Candidosis. D. THIENPONT, J. VAN CUTSEM, and M. BORGERES .....	570
Discussion .....	577
Session III: Dermatomycoses	
Oral Therapy with Ketoconazole for Dermatophyte Infections Unresponsive to Griseofulvin. MARGARET H. ROBERTSON, JON M. HANIFIN, and FRANK PARKER .....	578
Treatment of Dermatomycoses with Ketoconazole. OLIVERIO WELSH and MANUEL RODRIGUEZ .....	582
A Multi-Center, Double-Blind Comparison of Ketoconazole and Griseofulvin in the Treatment of Infections Due to Dermatophytes. ROBERT LEGENDRE and MICHAEL STELTZ .....	586
Treatment of Pityriasis Versicolor with Ketoconazole. DANTE BORELLI .....	592
The Activity of Ketoconazole in the Treatment of Onychomycosis. R. GALIMBERTI, R. NEGRONI, M. R. IGLESIA DE ELIAS COSTA, and A. M. CASALÁ .....	596
Discussion .....	598
Session IV: Candidosis	
Treatment of Chronic Mucocutaneous Candidosis with Ketoconazole: Preliminary Results of a Controlled, Double-Blind Clinical Trial. CHARLES H. KIRKPATRICK, ESKILD A. PETERSEN, and DAVID W. ALLING .....	599
Treatment of Chronic Mucocutaneous Candidosis with Ketoconazole: A Study of 12 Cases. R. J. HAY, R. S. WELLS, Y. M. CLAYTON, and H. J. WINGFIELD .....	600
Chronic Mucocutaneous Candidosis and Other Superficial and Systemic Mycoses Successfully Treated with Ketoconazole. EDOUARD DROUHET and BERTRAND DUPONT .....	606
Ketoconazole in Vulvovaginal Candidosis. FELIPE FREGOSO-DUEÑAS .....	620
Discussion .....	623
Session V: Systemic Mycoses	
Chemotherapy for the Systemic Mycoses: The Prelude to Ketoconazole. JOHN P. UTZ .....	625
Ketoconazole: A New Drug for the Treatment of Paracoccidioidomycosis. ANGELA RESTREPO, DAVID A. STEVENS, IVÁN GÓMEZ, EDUARDO LEIDERMAN, RODRIGO ANGEL, JESUALDO FUENTES, ABRAHAM ARANA, GLORIA MEJÍA, ANA C. VANEGAS, and MARYANN ROBLEDÓ .....	633
Ketoconazole in the Treatment of Paracoccidioidomycosis and Histoplasmosis. R. NEGRONI, A. M. ROBLES, A. ARECHAVALA, M. A. TUCULET, and R. GALIMBERTI .....	643
Treatment of Paracoccidioidomycosis, Candidosis, Chromomycosis, Lobomycosis, and Mycetoma with Ketoconazole: A Brief Summary. LUIS CARLOS CUCÉ, ELIZABETH L. WROCLAWSKI, and SEBASTIÃO A. P. SAMPAIO .....	650
Discussion .....	650

Therapeutic Evaluation of Ketoconazole in Patients with Coccidioidomycosis. OLIVERIO WELSH, JOSE G. GONZÁLEZ, MANUEL DIAZ, DAVID MADERO, and JUVENTINO GONZÁLEZ .....	651
Therapy of Disseminated or Pulmonary Coccidioidomycosis with Ketoconazole. CORSTIAAN BRASS, JOHN N. GALGIANI, SAMMY C. CAMPBELL, and DAVID A. STEVENS .....	656
Treatment of Coccidioidomycosis with Ketoconazole: Clinical and Laboratory Studies of 18 Patients. JOHN R. GRAYBILL, DORIS LUNDBERG, WILLIAM DONOVAN, HILLEL B. LEVINE, MANUEL DIAZ RODRIGUEZ, and DAVID J. DRUTZ .....	661
Session VI: Summary	
An Evaluation of Two Years of Clinical Experience with Ketoconazole. J. SYMOENS, M. MOENS, J. DOM, H. SCHEIJGROND, J. DONY, V. SCHUERMANS, R. LEGENDRE, and N. FINESTINE .....	674
Discussion and Concluding Remarks .....	688
Abstracts in Spanish .....	692

Volume 2

September-October 1980

Number 5

## Contents

### Review Articles

Screening to Control Infectious Diseases: Evaluation of Control Programs for Gonorrhea and Syphilis. GAVIN HART .....	701
Biohazards of Investigations on the Transmissible Spongiform Encephalopathies. MARK A. CHATIGNY and STANLEY B. PRUSINER .....	713
Community-Acquired Purulent Meningitis: A Review of 1,316 Cases During the Antibiotic Era, 1954-1976. P. JAN GEISELER, KENRAD E. NELSON, STUART LEVIN, K. T. REDDI, and VIJAI K. MOSES .....	725
Citrobacter Infections in Humans: Experience at the Seattle Veterans Administration Medical Center and a Review of the Literature. BENJAMIN A. LIPSKY, EDWARD W. HOOK III, ARLENE A. SMITH, and JAMES J. FLORDE .....	746
Infections in Patients with Hodgkin's Disease: A Clinical Study of 300 Consecutive Adult Patients. DAVID T. NOTTER, PETER L. GROSSMAN, SAUL A. ROSENBERG, and JACK S. REMINGTON .....	761
The Effect of Aging on Susceptibility to Infection. IAN D. GARDNER .....	801

### Classics in Infectious Diseases

Concerning the Epidemic of Spotted Fever in New England. ELISHA NORTH .....	811
---	-----

### Serial Feature. Phagocytic Cells in the Defense Against Infection

Phagocyte Strategy vs. Microbial Tactics. PETER DENSEN and GERALD L. MANDELL .....	817
Erratum (Plotkin, S. A., 2:434) .....	839

**Contents****Review Articles**

- In Vitro Susceptibilities of Nonfermentative Gram-Negative Bacilli Other than *Pseudomonas aeruginosa* to 32 Antimicrobial Agents. ROBERT J. FASS and JEAN BARNISHAN..... 841
- Cutaneous and Soft-Tissue Manifestations of Sepsis Due to Gram-Negative Enteric Bacilli. DANIEL M. MUSER..... 854
- Epidemiologic, Clinical, Laboratory, and Therapeutic Features of an Urban Outbreak of Chancroid in North America. G. W. HAMMOND, M. SLUTCHUK, J. SCATLIFF, E. SHERMAN, J. C. WILT, and A. R. RONALD..... 867
- Arthritis in Disease Due to *Neisseria meningitidis*. URS B. SCHAAD..... 880
- Group C Streptococcal Pneumonia: Report of a Fatal Case and Review of the Literature. ALAN M. STAMM and C. GLENN COBBS..... 889
- Herpes Simplex Virus Antigens and Antibodies: A Survey of Studies Based on Quantitative Immunoelectrophoresis. BENT FABER VESTERGAARD..... 899

**Serial Feature**

- Gram-Negative Anaerobic Bacilli: Their Role in Infection and Patterns of Susceptibility to Antimicrobial Agents. I. Little-Known *Bacteroides* Species. BARBARA D. KIRBY, W. LANCE GEORGE, VERA L. SUTTER, DIANE M. CITRON, and SYDNEY M. FINEGOLD..... 914

**Historical Article**

- Seasonality of Plague in Early Modern Europe: Swiss Epidemic of 1628-1630. EDWARD A. ECKERT..... 952

**Correspondence**

- Killed and Live Poliovirus Vaccines. A. J. BEALE..... 960
- Erratum (North, E., 2:811-816)..... 962
- Reviewers for Volume 2..... 963
- Index to Volume 2..... 965

